Device therapy in hypertrophic cardiomyopathy

References

• Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy – alcohol septal ablation vs. myectomy: a meta-analysis. Eur. Heart J.30, 1080–1087 (2009).
   PubMedGoogle Scholar
• Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation92, 2488–2495 (1995).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation102, 858–864 (2000).
   PubMed Web of Science ®Google Scholar
• Nugent AW, Daubeney PE, Chondros P et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation112, 1332–1338 (2005).
   PubMedGoogle Scholar
• Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation104, 2517–2524 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol.15, 1279–1285 (1990).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Olivotto I, Bellone P et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.39, 301–307 (2002).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation65, 1388–1394 (1982).
   PubMed Web of Science ®Google Scholar
• McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: influence on prognosis. Br. Heart J.46, 168–172 (1981).
   PubMedGoogle Scholar
• Savage DD, Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation59, 866–875 (1979).
   PubMed Web of Science ®Google Scholar
• Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br. Heart J.61, 178–181 (1989).
   PubMedGoogle Scholar
• Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.33, 1596–1601 (1999).
   PubMedGoogle Scholar
• Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med.342, 365–373 (2000).
   PubMed Web of Science ®Google Scholar
• Boriani G, Rapezzi C, Biffi M, Branzi A, Spirito P. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J. Cardiovasc. Electrophysiol.13, 954 (2002).
   PubMedGoogle Scholar
• Edwards RH, Kristinsson A, Warrell DA, Goodwin JF. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br. Heart J.32, 219–225 (1970).
   PubMedGoogle Scholar
• Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation82, 1995–2002 (1990).
   PubMed Web of Science ®Google Scholar
• Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation84, 686–696 (1991).
   PubMed Web of Science ®Google Scholar
• Thomson HL, Morris-Thurgood J, Atherton J, Frenneaux M. Reduced cardiopulmonary baroreflex sensitivity in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.31, 1377–1382 (1998).
   PubMed Web of Science ®Google Scholar
• Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.33, 2044–2051 (1999).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Piccininno M, Casey SA, Bernabo P, Spirito P. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am. J. Cardiol.91, 626–628 (2003).
   PubMedGoogle Scholar
• Spirito P, Watson RM, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. Am. J. Cardiol.60, 1137–1142 (1987).
   PubMedGoogle Scholar
• Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.15, 1521–1526 (1990).
   PubMed Web of Science ®Google Scholar
• Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med.342, 1778–1785 (2000).
   PubMed Web of Science ®Google Scholar
• Elliott PM, Gimeno B Jr, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet357, 420–424 (2001).
   PubMed Web of Science ®Google Scholar
• Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest.111, 209–216 (2003).
   PubMed Web of Science ®Google Scholar
• Moolman JC, Corfield VA, Posen B et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol.29, 549–555 (1997).
   PubMed Web of Science ®Google Scholar
• Spirito P, Autore C, Rapezzi C et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation119, 1703–1710 (2009).
   PubMed Web of Science ®Google Scholar
• Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart79, 331–336 (1998).
   PubMed Web of Science ®Google Scholar
• Spirito P, Rapezzi C, Autore C et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation90, 2743–2747 (1994).
   PubMed Web of Science ®Google Scholar
• Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol.42, 873–879 (2003).
   PubMed Web of Science ®Google Scholar
• Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med.348, 295–303 (2003).
   PubMed Web of Science ®Google Scholar
• McLeod CJ, Ommen SR, Ackerman MJ et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur. Heart J.28, 2583–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol.51, 1369–1374 (2008).
   PubMed Web of Science ®Google Scholar
• Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.56, 875–887 (2010).
   PubMed Web of Science ®Google Scholar
• O’Hanlon R, Grasso A, Roughton M et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.56, 867–874 (2010).
   PubMed Web of Science ®Google Scholar
• Melacini P, Maron BJ, Bobbo F et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart93, 708–710 (2007).
   PubMed Web of Science ®Google Scholar
• Jayatilleke I, Doolan A, Ingles J et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am. J. Cardiol.93, 1192–1194 (2004).
   PubMedGoogle Scholar
• Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J. Cardiovasc. Electrophysiol.13, 1183–1199 (2002).
   PubMedGoogle Scholar
• Maron BJ, Spirito P, Shen WK et al. Implantable cardioverter–defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA298, 405–412 (2007).
   PubMed Web of Science ®Google Scholar
• Lin G, Nishimura RA, Gersh BJ et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart95, 709–714 (2009).
   PubMed Web of Science ®Google Scholar
• Gilgenkrantz JM, Cherrier F, Petitier H, Dodinot B, Houplon M, Legoux J. [Obstructive cardiomyopathy of the left ventricle with complete auriculo-ventriculrar block. Therapeutic considerations]. Arch. Mal. Coeur Vaiss.61, 439–453 (1968).
   PubMedGoogle Scholar
• Hassenstein P, Wolter HH. [Therapeutic control of a threatening stage of idiopathic hypertrophic subaortic stenosis]. Verh. Dtsch. Ges. Kreislaufforsch.33, 242–246 (1967).
   PubMedGoogle Scholar
• Hassenstein P, Storch HH, Schmitz W. [Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy (author’s translation)]. Thoraxchir. Vask. Chir.23, 496–498 (1975).
   PubMedGoogle Scholar
• Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet339, 1318–1323 (1992).
   PubMed Web of Science ®Google Scholar
• Jeanrenaud X, Kappenberger L. Regional wall motion during pacing for hypertrophic obstructive cardiomyopathy. Pacing Clin. Electrophysiol.20, 1673–1681 (1997).
   PubMedGoogle Scholar
• Kappenberger L, Linde C, Daubert C et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur. Heart J.18, 1249–1256 (1997).
   PubMed Web of Science ®Google Scholar
• McDonald K, McWilliams E, O’Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur. Heart J.9, 893–898 (1988).
   PubMed Web of Science ®Google Scholar
• McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am. J. Cardiol.68, 108–110 (1991).
   PubMedGoogle Scholar
• Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation98, 242–248 (1998).
   PubMedGoogle Scholar
• Leclercq C, Gras D, Le Helloco A, Nicol L, Mabo P, Daubert C. Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing. Am. Heart J.129, 1133–1141 (1995).
   PubMedGoogle Scholar
• Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR Jr, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J. Am. Coll. Cardiol.27, 421–430 (1996).
   PubMed Web of Science ®Google Scholar
• Fananapazir L, Cannon RO, III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation85, 2149–2161 (1992).
   PubMed Web of Science ®Google Scholar
• Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation90, 2731–2742 (1994).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation99, 2927–2933 (1999).
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J. Am. Coll. Cardiol.29, 435–441 (1997).
   PubMed Web of Science ®Google Scholar
• Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J. Am. Coll. Cardiol.34, 191–196 (1999).
   PubMedGoogle Scholar
• Galve E, Sambola A, Saldana G et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart96, 352–356 (2010).
   PubMedGoogle Scholar
• Megevand A, Ingles J, Richmond DR, Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am. J. Cardiol.95, 991–993 (2005).
   PubMed Web of Science ®Google Scholar
• Woo A, Monakier D, Harris L et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart93(9), 1044–1045 (2007).
   PubMedGoogle Scholar
• Syska P, Przybylski A, Chojnowska L et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J. Cardiovasc. Electrophysiol.21(8), 883–889 (2010).
   PubMed Web of Science ®Google Scholar
• Maron BJ, Shen WK, Link MS et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med.342(6), 365–373 (2000).
   PubMed Web of Science ®Google Scholar